GlassScriptPhysician profile
Marc Irwin Rothman
NPI 1700884889
$503.51
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17.92 · 2020: $37.45 · 2021: $45.28 · 2022: $165 · 2023: $135 · 2024: $102.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $238.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $237.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $86.61 | 2019-2023 | Aristada, Lybalvi |
| Otsuka America Pharmaceutical, INC. | $72.28 | 2023-2024 | Rexulti |
| Lundbeck LLC | $58.54 | 2022-2023 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $49.36 | 2021-2024 | Caplyta |
| Tepha INC | $37.45 | 2020 | |
| Janssen Pharmaceuticals, INC | $32.92 | 2024 | Spravato |
| Idorsia Pharmaceuticals US INC | $29.87 | 2023-2024 | Quviviq |
| Noven Therapeutics, LLC | $28.99 | 2022 | |
| Almatica Pharma LLC | $26.14 | 2022 | |
| Avanir Pharmaceuticals, INC. | $25.96 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.71 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $14.61 | 2022 | |
| Neos Therapeutics, LP | $13.90 | 2021 | |
| Bausch Health US, LLC | $12.17 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marc Rothman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.